Alkermes Plc Insider Trading
Every director, officer and 10% holder of Alkermes Plc has to report each trade in its stock within two business days of making it. This is those filings.
ALKS on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| David Joseph GaffinEVP, CLO, Alkermes, Inc.2026-09-032K shat $48.01 | Sale10b5-1 plan | $97.7K |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer2026-09-019K shat $46.99 | Sale10b5-1 plan | $422.9K |
| Christian Todd NicholsSVP, Chief Commercial Officer2026-08-176.9K shat $49.19 | Sale10b5-1 plan | $340K |
| Christian Todd NicholsSVP, Chief Commercial Officer2026-08-17664 shat $49.65 | Sale10b5-1 plan | $33K |
| nancy lynn MD snydermanDirector2026-08-0344.5K shat $50.35 | Sale | $2.2M |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer2026-08-039K shat $48.58 | Sale10b5-1 plan | $437.2K |
| David Joseph GaffinEVP, CLO, Alkermes, Inc.2026-08-032K shat $48.58 | Sale10b5-1 plan | $98.8K |
| David Joseph GaffinEVP, CLO, Alkermes, Inc.2026-07-062K shat $54.03 | Sale10b5-1 plan | $109.9K |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer2026-07-018.3K shat $51.46 | Sale10b5-1 plan | $427.1K |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer2026-07-01700 shat $52.13 | Sale10b5-1 plan | $36.5K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on ALKS
Follow Alkermes Plc (ALKS) by email
New trades in Alkermes Plc (ALKS) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.